



**3 February 2021 | CannPal Animal Therapeutics Limited | ASX: CP1  
ASX ANNOUNCEMENT**

**Registration of Scheme Booklet**

CannPal Animal Therapeutics Limited (ASX: CP1) ("CannPal" or "the Company") is pleased to announce that the Australian Securities and Investments Commission ("ASIC") has registered the Scheme Booklet relating to the proposed acquisition of CannPal by AusCann Group Holdings Ltd (ASX: AC8) ("AusCann") by way of a Scheme of Arrangement ("Scheme").

This announcement follows CannPal's announcement regarding the issuance of orders made by the Supreme Court of Western Australia approving despatch of the Scheme Booklet to CannPal shareholders and the convening of a meeting of CannPal shareholders to consider and vote on the Scheme ("Scheme Meeting").

**Despatch of Scheme Booklet**

The Scheme Booklet will be despatched to CannPal's shareholders on or before 4 February 2021.

CannPal shareholders who have elected to receive communications electronically will receive an email which contains instructions about how the Scheme Booklet can be viewed or downloaded, as well as instructions on how to lodge their proxy form for the meeting online.

CannPal shareholders who have not elected to receive communications electronically will be sent a personalised proxy form and instructions about how an electronic copy of the Scheme Booklet can be viewed or downloaded.

Any CannPal shareholder who would like a printed copy of the Scheme Booklet and proxy form may request one to be sent to them free of charge by contacting the Company Secretary on the telephone number stated below. An electronic copy of the Scheme Booklet will be available for viewing and downloading on the Company's website at [www.cannpal.com](http://www.cannpal.com) and the Company's ASX Announcement platform at [www.asx.com.au](http://www.asx.com.au).

**Independent Expert's Conclusion and Directors Recommendation**

The Scheme Booklet includes an Independent Expert's Report from KPMG Financial Advisory Services (Australia) Pty Ltd (**Independent Expert**) which concludes that the Scheme is fair and reasonable and in the best interest of CannPal shareholders, in the absence of a superior proposal. The Independent Expert's conclusion should be read in context with the full Independent Expert's Report and the Scheme Booklet.

The Directors of CannPal have unanimously recommended that, in the absence of a superior proposal and on the basis that the Independent Expert maintains its opinion that the Scheme is in the best interest of shareholders, CannPal shareholders vote in favour of the Scheme.

**Further Information**

If you are unable to access any of the documents online, or have any questions, please contact the Company Secretary, Mr Baden Bowen on 0402 339 443.

### **About CannPal Animal Therapeutics Limited**

CannPal Animal Therapeutics Limited (ASX: CP1) is an animal health Company with a mission to provide pet owners and veterinarians with access to high quality, evidence based, plant derived therapeutic products to promote better health and well-being for animals.

To learn more please visit: [www.cannpal.com](http://www.cannpal.com)

This announcement has been approved and authorised to be given to ASX by the Board of Directors of CannPal.

**ENDS**

---

**For further information, please contact:**

### **CannPal Animal Therapeutics Limited**

Layton Mills

Managing Director

M: 0431 302 667

E: [Layton@cannpal.com](mailto:Layton@cannpal.com)